Today: 21 May 2026
Browse Category

NASDAQ:CVNA 30 October 2025 - 22 December 2025

Carvana Stock (CVNA) Slides on S&P 500 Debut: Today’s News, Analyst Forecasts, and the Key Risks Bulls Can’t Ignore

Carvana Stock (CVNA) Slides on S&P 500 Debut: Today’s News, Analyst Forecasts, and the Key Risks Bulls Can’t Ignore

Carvana shares fell 4.33% to $430.75 Monday after joining the S&P 500 before the open, despite heavy trading volume of about 3.9 million shares. The stock opened near $452.33 and ranged between $429.69 and $457.47 during the session. Carvana’s index inclusion follows a surge of over 8,000% from 2022 lows near $3–$4 to a recent high of $485.33 on Dec. 12.
22 December 2025
·
Stock Market Today, December 8, 2025: Wall Street Edges Higher as Fed Rate Cut Looms and Broadcom, Confluent, Carvana Lead Premarket Moves

Stock Market Today, December 8, 2025: Wall Street Edges Higher as Fed Rate Cut Looms and Broadcom, Confluent, Carvana Lead Premarket Moves

U.S. stock index futures edged higher early Monday as investors awaited the Federal Reserve’s expected third consecutive rate cut, with CME data showing an 87–88% probability of a quarter-point move. President Donald Trump’s warning over Netflix’s $72 billion bid for Warner Bros Discovery raised new regulatory concerns. Warner Bros Discovery shares jumped over 6% Friday after the deal was announced, while Netflix slipped.
8 December 2025
········
Stock Market Pre‑Market Today (Dec 8, 2025): Futures Edge Higher as Fed Rate Cut Looms, Top Gainers and Losers

Stock Market Pre‑Market Today (Dec 8, 2025): Futures Edge Higher as Fed Rate Cut Looms, Top Gainers and Losers

S&P 500 futures rose 0.11% and Nasdaq 100 futures gained 0.21% in early pre-market trading Monday as investors await a widely expected Fed rate cut on Wednesday. Carvana surged on news of its S&P 500 inclusion, while Confluent jumped on takeover speculation. Micro-cap biotech stocks led declines. Futures markets price in an 85–89% chance of a quarter-point cut, but focus remains on Fed signals for 2026.
8 December 2025
····
1 2 3

Stock Market Today

  • SpaceX IPO Filing Reveals Financials, Musk Could Become First Trillionaire
    May 20, 2026, 7:08 PM EDT. SpaceX filed for an initial public offering (IPO), disclosing its finances and board members for the first time. The company reported $18.7 billion in revenue for 2025, up 33% year-on-year, but posted a net loss of $4.9 billion, reversing a $791 million profit in 2024. First-quarter 2026 losses reached $4.3 billion on $4.7 billion revenue. The IPO, trading as SPCX, may become the largest ever, potentially boosting Elon Musk's wealth to trillionaire status. SpaceX aims to fund its ambitious plans including Starlink satellite network expansion, AI infrastructure, and establishing extraterrestrial colonies.

Latest articles

SPAC ETF Up as SpaceX Heads for SPCX Ticker

SPAC ETF Up as SpaceX Heads for SPCX Ticker

21 May 2026
The SPAC and New Issue ETF, now trading as SPCK, closed up 0.64% at $22.09 on Wednesday after SpaceX filed for a $75 billion IPO under the fund’s old ticker. The fund reported $7.14 million in net assets and 41 holdings as of May 19. New listings included a $75 million IPO from Research Alliance III and filings from FutureCorp Space Acquisition 1 and JAB Acquisition I. The SEC proposed easing share issuance rules for public companies.
EnerSys Stock Flips After Earnings as Guidance Tops Trader Hopes

EnerSys Stock Flips After Earnings as Guidance Tops Trader Hopes

21 May 2026
EnerSys shares rose in after-hours trading after the company posted fourth-quarter adjusted earnings of $3.19 per share on $988 million in revenue, both above analyst estimates. The stock closed regular hours down 1.3% at $214.56, then quoted up 5.8% to $227. First-quarter profit guidance also topped forecasts. Management cited strong data center and defense demand, but noted continued weakness in motive-power and transportation.
Silexion Soars After Cancer Study, Liquidity and Nasdaq Issues Linger for SLXN

Silexion Soars After Cancer Study, Liquidity and Nasdaq Issues Linger for SLXN

21 May 2026
Silexion Therapeutics shares surged 97% to $0.5298 on Wednesday with over 325 million shares traded, then fell 9.5% after hours. The move followed news that Israel approved a Phase 2/3 trial of its lead pancreatic cancer drug, SIL204. Silexion reported a Q1 net loss of $2.7 million and $2.4 million in cash. The company plans a 1-for-10 reverse share split by early June.
Go toTop